– Dr. Prabhavathi Fernandes elected as member of the Supervisory Board
Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis”), a developer of next-level molecular diagnostic solutions, today reported the results of its Annual Shareholder Meeting (“AGM”) held in Amsterdam on June 16, 2016.
The shareholders approved all items on the agenda of the AGM, including the election of Dr. Prabhavathi Fernandes (CEO of Cempra Pharmaceuticals, Inc., Chapel Hill, NC, USA) as a member of Curetis´ Supervisory Board for a three-year term until 2019. Prabhavathi Fernandes has profound knowledge in infectious diseases and antibiotics as well as experience in successfully founding, building up and leading several biotech companies and taking one public on Nasdaq raising more than half a billion dollars.
Moreover, Dr. Holger Reithinger and Dr. Rudy Dekeyser were re-elected for another one-year term, respectively. In addition, the proposed resignation of Dr. Frank Mühlenbeck, the creation of a new Stock Option Program for the Company and associated changes to the Supervisory Board remuneration policy as well as changes to the Management Board’s Remuneration Policy and Stock Option grants were also approved by the shareholders.
“We are excited about the election of Prabha Fernandes to our board,” said Oliver Schacht, CEO of Curetis. “She brings unparalleled MDx industry expertise and will play a crucial role in helping Curetis prepare for the planned market launch in the US. Moreover, we are pleased that all proposed AGM resolutions have been approved by our shareholders.”